'Hypometabolic' and 'Photopenic' — What Your PET Report Is Telling You

A photopenic defect in the liver means a localised area that absorbed less FDG than the surrounding liver tissue. The liver absorbs a moderate amount of tracer normally, so a darker area within it stands out. This can be a simple cyst, a haemangioma (a benign cluster of blood vessels), or a tumour deposit that does not absorb much glucose. The CT images taken at the same time as your PET usually clarify the structure — whether it has smooth edges, fluid inside, or features that need closer attention. Your radiologist reports on PET and CT together. Ask your oncologist specifically what the CT showed in the same location before drawing any conclusions from the PET appearance alone.

A lesion that was bright before treatment and is now dark after treatment has taken up less glucose in response to the therapy. This is generally what treatment response looks like on a PET scan. It does not automatically mean the cancer is gone — residual scar tissue, viable tumour below the scanner's detection threshold, and treated-but-not-eradicated disease can all look similar on imaging. Your oncologist will weigh the PET findings alongside CT, blood markers if relevant, and your overall clinical picture before drawing a conclusion. ESMO and ASCO guidance emphasises that imaging response criteria vary by cancer type and must be interpreted by a specialist in context.

Yes, and this is an important limitation of FDG-PET. Some cancers — including certain liver cancers, mucinous adenocarcinomas, some low-grade lymphomas, and prostate cancers — do not reliably absorb FDG even when they are active. In these cancer types, a dark or photopenic PET finding does not confirm that an area is clear of disease. Your oncologist will tell you if your cancer type is one where FDG-PET is not the most reliable tool, and may use CT, MRI, or a different tracer that is more specific to your cancer's biology.

These are all different words for the same observation — reduced or absent FDG tracer uptake in an area. Hypometabolic emphasises the biology: reduced glucose metabolism. Photopenic emphasises the imaging physics: fewer detected photons, so a darker image. Cold is informal shorthand borrowed from nuclear medicine, meaning low or absent uptake. Non-avid means the tissue does not accumulate the tracer significantly. None of these is more alarming than the others; radiologists use them interchangeably depending on their training and the reporting conventions they follow. The clinical meaning in your case comes from context, not from the specific word chosen.

Not always. The decision depends on whether the finding would change what your treatment team does next, whether the CT images are reassuring, and whether the finding is new or has been stable across several scans. A well-defined, stable photopenic area with smooth edges on CT is often followed with repeat imaging rather than biopsied. A new, growing, or structurally ambiguous finding is more likely to prompt tissue sampling. Ask your oncologist specifically whether a biopsy is being considered and what it would change about your care plan. That is a direct and reasonable question to put to your team.

The brain runs almost entirely on glucose and absorbs FDG continuously and heavily, making it one of the brightest organs on a normal PET scan. This background brightness can make nearby findings harder to assess, because a lesion that would stand out clearly in another organ may be less visible against the brain's own uptake. Brain PET is assessed differently from body PET for this reason, and MRI usually provides more reliable structural detail in the head. If your report mentions a photopenic or hypometabolic finding near or within the brain, your oncologist will interpret it in the context of MRI findings alongside the PET.